Researchers from the Weizmann Institute of Science in Israel and Clalit Health Services have found that sildenafil, the active ingredient in Viagra, may improve survival rates in male cancer patients. The study, published in Cancer Research, analyzed over 20 years of anonymized medical data from approximately 5 million people, including 40,000 men diagnosed with cancer. Men who had taken sildenafil before their cancer diagnosis showed better overall survival compared to those who had not. The effect was even stronger in men who also took statins.
The researchers said sildenafil appears to block cancer cells' access to cholesterol, a substance cancer cells need to break away from primary tumors and spread. Laboratory studies on mice and human cancer cell cultures supported this mechanism. However, the study only looked at pre-diagnosis use of sildenafil and did not assess whether taking the drug after diagnosis affects outcomes. It also did not evaluate effects in women, as sildenafil is primarily prescribed to men.
The findings come from a retrospective analysis, meaning they show an association but not a proven cause-and-effect relationship. Experts including Dr. Mike Lattanzi of Texas Oncology noted the results are preclinical and require validation in human trials before any change in cancer treatment. Dr. Samah Hayek of the Clalit Research Institute said more research, including clinical trials, is needed to determine if sildenafil could become part of cancer therapy.
The study links pre-diagnosis sildenafil use to better survival in men but offers no evidence it helps after cancer is detected. This leaves patients and doctors without guidance on whether taking Viagra post-diagnosis could make a difference. Without trials involving women or post-diagnosis use, the findings remain limited to a historical association.
Editorial note: AI-assisted opinion, not established fact. Full disclaimer →
